BioPharma Resources

Drug Trial Radar · NCT02000089

The Cancer of the Pancreas Screening-5 CAPS5)Study

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

9,000

Planned (sponsor's estimate)

Start

Jan 6, 2014

Primary completion

Dec 2028

Study completion Jun 2029

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI); National Institutes of Health (NIH); American Association for Cancer Research
First posted
Dec 3, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

Conditions

  • Pancreas Cancer
  • Peutz-Jeghers Syndrome (PJS)
  • Gene Mutation
  • Germline Mutation Carrier
  • Lynch Syndrome

Interventions

  • SecretinDrug

    inject Secretin to stimulate pancreatic digestive fluid, which is collected in duodenum near ampulla via endoscope suction port. This fluid will be assessed for biomarkers.

  • MRIDiagnostic test

    MRI abdomen with contrast (MRCP) will be clinically indicated for abnormal novel CA-19-9 lab results.

  • Tumor marker gene test with CA19-9Other

    A tumor marker gene test that will be used to stratify individuals into one of several circulating tumor marker reference ranges for CA19-9. The variants in the genes FUT3 and FUT2 affect the levels of CA19-9.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate pancreatic juice for early cancer markers.Time frame: 10 years

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Yale University

    New Haven, Connecticut · Recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • Dana Farber Cancer Center, Harvard University

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • NYU Langone Medical Center

    New York, New York · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Case Comprehensive Cancer Center, Case Western Medical Reserve

    Cleveland, Ohio · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.